Global Drugs for Vulvovaginal Candidiasis Market Growth 2020-2025

Publisher Name :
Date: 01-Oct-2020
No. of pages: 133

According to this study, over the next five years the Drugs for Vulvovaginal Candidiasis market will register a 1.6%% CAGR in terms of revenue, the global market size will reach $ 823.8 million by 2025, from $ 774.4 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Vulvovaginal Candidiasis business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Drugs for Vulvovaginal Candidiasis, covering the supply chain analysis, impact assessment to the Drugs for Vulvovaginal Candidiasis market size growth rate in several scenarios, and the measures to be undertaken by Drugs for Vulvovaginal Candidiasis companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.

- Miconazole

- Clotrimazole

- Fluconazole

- Econazole

- Other

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.

- Hospital & Clinic

- Pharmacy

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

- Americas

- United States

- Canada

- Mexico

- Brazil

- APAC

- China

- Japan

- Korea

- Southeast Asia

- India

- Australia

- Europe

- Germany

- France

- UK

- Italy

- Russia

- Middle East & Africa

- Egypt

- South Africa

- Israel

- Turkey

- GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

- Bayer

- Kingyork Group

- Perrigo

- Pfizer

- Bristol-Myers Squibb

- J & J

- Sanofi

- Effik

- Cisen Pharmaceutical

- Teva

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

- To study and analyze the global Drugs for Vulvovaginal Candidiasis consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.

- To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.

- Focuses on the key global Drugs for Vulvovaginal Candidiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

- To analyze the Drugs for Vulvovaginal Candidiasis with respect to individual growth trends, future prospects, and their contribution to the total market.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- To project the consumption of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

- To strategically profile the key players and comprehensively analyze their growth strategies.

Global Drugs for Vulvovaginal Candidiasis Market Growth 2020-2025

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption 2015-2025
2.1.2 Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region
2.2 Drugs for Vulvovaginal Candidiasis Segment by Type
2.2.1 Miconazole
2.2.2 Clotrimazole
2.2.3 Fluconazole
2.2.4 Econazole
2.2.5 Other
2.3 Drugs for Vulvovaginal Candidiasis Consumption by Type
2.3.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2015-2020)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2015-2020)
2.4 Drugs for Vulvovaginal Candidiasis Segment by Application
2.4.1 Hospital & Clinic
2.4.2 Pharmacy
2.5 Drugs for Vulvovaginal Candidiasis Consumption by Application
2.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
2.5.2 Global Drugs for Vulvovaginal Candidiasis Value and Market Share by Type (2015-2020)
2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2015-2020)

3 Global Drugs for Vulvovaginal Candidiasis by Company
3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Company (2018-2020)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2018-2020)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company
3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2018-2020)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2018-2020)
3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Company
3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Drugs for Vulvovaginal Candidiasis by Regions
4.1 Drugs for Vulvovaginal Candidiasis by Regions
4.2 Americas Drugs for Vulvovaginal Candidiasis Consumption Growth
4.3 APAC Drugs for Vulvovaginal Candidiasis Consumption Growth
4.4 Europe Drugs for Vulvovaginal Candidiasis Consumption Growth
4.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Growth

5 Americas
5.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries
5.1.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020)
5.1.2 Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020)
5.2 Americas Drugs for Vulvovaginal Candidiasis Consumption by Type
5.3 Americas Drugs for Vulvovaginal Candidiasis Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Regions
6.1.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Regions (2015-2020)
6.1.2 APAC Drugs for Vulvovaginal Candidiasis Value by Regions (2015-2020)
6.2 APAC Drugs for Vulvovaginal Candidiasis Consumption by Type
6.3 APAC Drugs for Vulvovaginal Candidiasis Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries
7.1.1 Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020)
7.1.2 Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020)
7.2 Europe Drugs for Vulvovaginal Candidiasis Consumption by Type
7.3 Europe Drugs for Vulvovaginal Candidiasis Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Countries
8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020)
8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type
8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Drugs for Vulvovaginal Candidiasis Distributors
10.3 Drugs for Vulvovaginal Candidiasis Customer

11 Global Drugs for Vulvovaginal Candidiasis Market Forecast
11.1 Global Drugs for Vulvovaginal Candidiasis Consumption Forecast (2021-2025)
11.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions
11.2.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions (2021-2025)
11.2.2 Global Drugs for Vulvovaginal Candidiasis Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
11.8 Global Drugs for Vulvovaginal Candidiasis Forecast by Application

12 Key Players Analysis
12.1 Bayer
12.1.1 Company Information
12.1.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Bayer Latest Developments
12.2 Kingyork Group
12.2.1 Company Information
12.2.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.2.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Kingyork Group Latest Developments
12.3 Perrigo
12.3.1 Company Information
12.3.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.3.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Perrigo Latest Developments
12.4 Pfizer
12.4.1 Company Information
12.4.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Pfizer Latest Developments
12.5 Bristol-Myers Squibb
12.5.1 Company Information
12.5.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Bristol-Myers Squibb Latest Developments
12.6 J & J
12.6.1 Company Information
12.6.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.6.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 J & J Latest Developments
12.7 Sanofi
12.7.1 Company Information
12.7.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.7.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Sanofi Latest Developments
12.8 Effik
12.8.1 Company Information
12.8.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.8.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Effik Latest Developments
12.9 Cisen Pharmaceutical
12.9.1 Company Information
12.9.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Cisen Pharmaceutical Latest Developments
12.10 Teva
12.10.1 Company Information
12.10.2 Drugs for Vulvovaginal Candidiasis Product Offered
12.10.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Teva Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Research Methodology
Table 2. Data Source
Table 3. Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Miconazole
Table 5. Major Players of Clotrimazole
Table 6. Major Players of Fluconazole
Table 7. Major Players of Econazole
Table 8. Major Players of Other
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2015-2020) ($ million)
Table 12. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Table 16. Global Drugs for Vulvovaginal Candidiasis Value by Application (2015-2020)
Table 17. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Application (2015-2020)
Table 18. Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2015-2020)
Table 19. Global Drugs for Vulvovaginal Candidiasis Sales by Company (2017-2019) (K Units)
Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2017-2019)
Table 21. Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2017-2019)
Table 23. Global Drugs for Vulvovaginal Candidiasis Sale Price by Company (2017-2019)
Table 24. Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Drugs for Vulvovaginal Candidiasis Products Offered
Table 26. Drugs for Vulvovaginal Candidiasis Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Drugs for Vulvovaginal Candidiasis Consumption by Regions 2015-2020 (K Units)
Table 28. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Regions 2015-2020
Table 29. Global Drugs for Vulvovaginal Candidiasis Value by Regions 2015-2020 ($ Millions)
Table 30. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Regions 2015-2020
Table 31. Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2015-2020)
Table 33. Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2015-2020)
Table 35. Americas Drugs for Vulvovaginal Candidiasis Consumption by Type (2015-2020) (K Units)
Table 36. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Table 37. Americas Drugs for Vulvovaginal Candidiasis Consumption by Application (2015-2020) (K Units)
Table 38. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Table 39. APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020) (K Units)
Table 40. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2015-2020)
Table 41. APAC Drugs for Vulvovaginal Candidiasis Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Drugs for Vulvovaginal Candidiasis Value Market Share by Regions (2015-2020)
Table 43. APAC Drugs for Vulvovaginal Candidiasis Consumption by Type (2015-2020) (K Units)
Table 44. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Table 45. APAC Drugs for Vulvovaginal Candidiasis Consumption by Application (2015-2020) (K Units)
Table 46. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Table 47. Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2015-2020)
Table 49. Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2015-2020)
Table 51. Europe Drugs for Vulvovaginal Candidiasis Consumption by Type (2015-2020) (K Units)
Table 52. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Table 53. Europe Drugs for Vulvovaginal Candidiasis Consumption by Application (2015-2020) (K Units)
Table 54. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Drugs for Vulvovaginal Candidiasis Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Table 63. Drugs for Vulvovaginal Candidiasis Distributors List
Table 64. Drugs for Vulvovaginal Candidiasis Customer List
Table 65. Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Drugs for Vulvovaginal Candidiasis Consumption Market Forecast by Regions
Table 67. Global Drugs for Vulvovaginal Candidiasis Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Regions
Table 69. Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Drugs for Vulvovaginal Candidiasis Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Type (2021-2025)
Table 73. Global Drugs for Vulvovaginal Candidiasis Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Drugs for Vulvovaginal Candidiasis Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Drugs for Vulvovaginal Candidiasis Value Market Share Forecast by Application (2021-2025)
Table 77. Bayer Product Offered
Table 78. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 79. Bayer Main Business
Table 80. Bayer Latest Developments
Table 81. Bayer Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 82. Kingyork Group Product Offered
Table 83. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 84. Kingyork Group Main Business
Table 85. Kingyork Group Latest Developments
Table 86. Kingyork Group Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 87. Perrigo Product Offered
Table 88. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 89. Perrigo Main Business
Table 90. Perrigo Latest Developments
Table 91. Perrigo Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 92. Pfizer Product Offered
Table 93. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 94. Pfizer Main Business
Table 95. Pfizer Latest Developments
Table 96. Pfizer Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 97. Bristol-Myers Squibb Product Offered
Table 98. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 99. Bristol-Myers Squibb Main Business
Table 100. Bristol-Myers Squibb Latest Developments
Table 101. Bristol-Myers Squibb Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 102. J & J Product Offered
Table 103. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 104. J & J Main Business
Table 105. J & J Latest Developments
Table 106. J & J Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 107. Sanofi Product Offered
Table 108. Sanofi Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Main Business
Table 110. Sanofi Latest Developments
Table 111. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 112. Effik Product Offered
Table 113. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 114. Effik Main Business
Table 115. Effik Latest Developments
Table 116. Effik Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 117. Cisen Pharmaceutical Product Offered
Table 118. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 119. Cisen Pharmaceutical Main Business
Table 120. Cisen Pharmaceutical Latest Developments
Table 121. Cisen Pharmaceutical Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 122. Teva Product Offered
Table 123. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 124. Teva Main Business
Table 125. Teva Latest Developments
Table 126. Teva Basic Information, Company Total Revenue (in $ million), Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors

List of Figures

Figure 1. Picture of Drugs for Vulvovaginal Candidiasis
Figure 2. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Drugs for Vulvovaginal Candidiasis Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Drugs for Vulvovaginal Candidiasis Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Miconazole
Figure 7. Product Picture of Clotrimazole
Figure 8. Product Picture of Fluconazole
Figure 9. Product Picture of Econazole
Figure 10. Product Picture of Other
Figure 11. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2015-2020)
Figure 12. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Type (2015-2020)
Figure 13. Drugs for Vulvovaginal Candidiasis Consumed in Hospital & Clinic
Figure 14. Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic (2015-2020) (K Units)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic (2015-2020) ($ Millions)
Figure 16. Drugs for Vulvovaginal Candidiasis Consumed in Pharmacy
Figure 17. Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy (2015-2020) (K Units)
Figure 18. Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy (2015-2020) ($ Millions)
Figure 19. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2015-2020)
Figure 20. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Application (2015-2020)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2017
Figure 22. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company in 2019
Figure 23. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company in 2017
Figure 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company in 2019
Figure 25. Global Drugs for Vulvovaginal Candidiasis Sale Price by Company in 2019
Figure 26. Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Regions 2015-2020
Figure 27. Global Drugs for Vulvovaginal Candidiasis Value Market Share by Regions 2015-2020
Figure 28. Americas Drugs for Vulvovaginal Candidiasis Consumption 2015-2020 (K Units)
Figure 29. Americas Drugs for Vulvovaginal Candidiasis Value 2015-2020 ($ Millions)
Figure 30. APAC Drugs for Vulvovaginal Candidiasis Consumption 2015-2020 (K Units)
Figure 31. APAC Drugs for Vulvovaginal Candidiasis Value 2015-2020 ($ Millions)
Figure 32. Europe Drugs for Vulvovaginal Candidiasis Consumption 2015-2020 (K Units)
Figure 33. Europe Drugs for Vulvovaginal Candidiasis Value 2015-2020 ($ Millions)
Figure 34. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption 2015-2020 (K Units)
Figure 35. Middle East & Africa Drugs for Vulvovaginal Candidiasis Value 2015-2020 ($ Millions)
Figure 36. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2019
Figure 37. Americas Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2019
Figure 38. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2019
Figure 39. Americas Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2019
Figure 40. United States Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 41. United States Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 42. Canada Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 43. Canada Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 44. Mexico Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 45. Mexico Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 46. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2019
Figure 47. APAC Drugs for Vulvovaginal Candidiasis Value Market Share by Regions in 2019
Figure 48. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2019
Figure 49. APAC Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2019
Figure 50. China Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 51. China Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 52. Japan Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 53. Japan Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 54. Korea Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 55. Korea Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 56. Southeast Asia Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 57. Southeast Asia Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 58. India Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 59. India Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 60. Australia Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 61. Australia Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 62. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2019
Figure 63. Europe Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2019
Figure 64. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2019
Figure 65. Europe Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2019
Figure 66. Germany Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 67. Germany Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 68. France Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 69. France Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 70. UK Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 71. UK Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 72. Italy Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 73. Italy Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 74. Russia Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 75. Russia Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 76. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Countries in 2019
Figure 77. Middle East & Africa Drugs for Vulvovaginal Candidiasis Value Market Share by Countries in 2019
Figure 78. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type in 2019
Figure 79. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2019
Figure 80. Egypt Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 81. Egypt Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 82. South Africa Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 83. South Africa Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 84. Israel Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 85. Israel Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 86. Turkey Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 87. Turkey Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 88. GCC Countries Drugs for Vulvovaginal Candidiasis Consumption Growth 2015-2020 (K Units)
Figure 89. GCC Countries Drugs for Vulvovaginal Candidiasis Value Growth 2015-2020 ($ Millions)
Figure 90. Global Drugs for Vulvovaginal Candidiasis Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 91. Global Drugs for Vulvovaginal Candidiasis Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 92. Americas Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 93. Americas Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 94. APAC Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 95. APAC Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 96. Europe Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 97. Europe Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 98. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 99. Middle East & Africa Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 100. United States Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 101. United States Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 102. Canada Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 103. Canada Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 104. Mexico Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 105. Mexico Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 106. Brazil Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 107. Brazil Drugs for Vulvovaginal Candidiasis Value 2021-2025 ($ Millions)
Figure 108. China Drugs for Vulvovaginal Candidiasis Consumption 2021-2025 (K Units)
Figure 109. China Drugs for Vulvovaginal Candidiasis Value 2021-2025
  • Global and China Endometriosis Drugs Market Size, Status and Forecast 2020-2026
    Published: 14-Oct-2020        Price: US 3900 Onwards        Pages: 98
    Global Endometriosis Drugs Scope and Market Size Endometriosis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Endometriosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026. Market segment by Type, the product can be split ......
  • Global and China Assisted Reproductive Technology Market Size, Status and Forecast 2020-2026
    Published: 09-Oct-2020        Price: US 3900 Onwards        Pages: 90
    Global Assisted Reproductive Technology Scope and Market Size Assisted Reproductive Technology market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Assisted Reproductive Technology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026. Market seg......
  • (COVID-19 Version) Global Contraceptives Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use
    Published: 08-Oct-2020        Price: US 3000 Onwards        Pages: 87
    Summary The report forecast global Contraceptives market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Contraceptives industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Contraceptives by geography. The repor......
  • Global Assisted Reproductive Technology Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)
    Published: 08-Oct-2020        Price: US 3400 Onwards        Pages: 107
    The Assisted Reproductive Technology market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Assisted Reproductive Technology market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Assisted Reproductive Technology market. The report focuses on well-known providers in the global Assisted Reproductive Te......
  • Global and China Topical Contraceptive Market Insights, Forecast to 2026
    Published: 01-Oct-2020        Price: US 3900 Onwards        Pages: 134
    Topical Contraceptive market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Topical Contraceptive market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Topical Contraceptive market ......
  • Global Drugs for Vulvovaginal Candidiasis Market Growth 2020-2025
    Published: 01-Oct-2020        Price: US 3660 Onwards        Pages: 133
    According to this study, over the next five years the Drugs for Vulvovaginal Candidiasis market will register a 1.6%% CAGR in terms of revenue, the global market size will reach $ 823.8 million by 2025, from $ 774.4 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Vulvovaginal Candidiasis business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities......
  • Global and China Bacterial Vaginosis Drugs Market Insights, Forecast to 2026
    Published: 30-Sep-2020        Price: US 3900 Onwards        Pages: 125
    Bacterial Vaginosis Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Bacterial Vaginosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Bacterial Vaginosis D......
  • (COVID-19 Version) Global Topical Contraceptive Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use
    Published: 30-Sep-2020        Price: US 3000 Onwards        Pages: 123
    Summary The report forecast global Topical Contraceptive market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Topical Contraceptive industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Topical Contraceptive by......
  • Polycystic Ovarian Syndrome - Pipeline Review, H2 2020
    Published: 30-Sep-2020        Price: US 2000 Onwards        Pages: 55
    Polycystic Ovarian Syndrome - Pipeline Review, H2 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2020, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the sc......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs